<DOC>
	<DOCNO>NCT00826267</DOCNO>
	<brief_summary>An open-label , randomized three-arm Phase II trial explore efficacy BIBW 2992 single agent versus lapatinib versus trastuzumab patient HER2-positive treatment-na√Øve Stage IIIa locally advance breast cancer . Additional information obtain safety profile pharmacokinetics BIBW 2992 .</brief_summary>
	<brief_title>6 Weeks Treatment Locally Advanced Breast Cancer With BIBW 2992 ( Afatinib ) Lapatinib Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Female , age 18 year old . 2 . Histologically proven breast cancer receive prior therapy . 3 . Locally advanced disease Stage IIIa evidence distant metastatic disease anatomical site lymph node . 4 . HER2positive . Exclusion criterion : 1 . Absolute neutrophil count ( ANC ) less 1500/mm3 . 2 . Platelet count less 100 000/ mm3 . 3 . Hemoglobin level le 9.0 g/dl . 4 . Bilirubin great 1.5 mg/dI . 5 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great twice upper limit normal . 6 . Serum creatinine great 1.5 time upper normal limit . 7 . Significant recent acute gastrointestinal disorder diarrhea 8 . Pregnancy breastfeed . 9 . Organ system dysfunction include cardiac ( LVEF &lt; 50 % ) . 10 . Prior chemotherapy , radiotherapy hormone therapy . Previous treatment trastuzumab , EGFR , EGFR/HER2inhibitors . 11 . Other malignancy diagnose within past five year . 12 . Serious active infection . HIV , active hepatitis B C .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>